[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603460":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":29,"locations":26,"responsibleParty":35,"collaborators":26,"id":37,"slug":38,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":26,"eligibilityCriteria":43,"healthyVolunteers":39,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":26,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":26,"overallStatus":56,"whyStopped":26,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":26},{"fullName":5,"class":6},"VivaVision Biotech, Inc","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"VVN461, 1.0%","EXPERIMENTAL","VVN461 Ophthalmic Solution, 1.0%",[13],"Drug: VVN461 Ophthalmic Solution 1.0%",{"label":15,"type":16,"description":17,"interventionNames":18},"1.0% prednisolone acetate","ACTIVE_COMPARATOR","1.0% prednisolone acetate, Pred Forte",[19],"Drug: 1.0% prednisolone acetate",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","VVN461 Ophthalmic Solution 1.0%","1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days",[9],null,{"type":22,"name":15,"description":24,"armGroupLabels":28,"otherNames":26},[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":26,"email":34},"Caroline Lu","CONTACT","+8618816562189","caroline.lu@vivavisionbio.com",{"type":36,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100603460","phase-3-a-phase-3-study-of-vvn461-ophthalmic-solution-for-noninfectious-anterior-uveitis-100603460",false,"NCT07136805","A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","A Multi-center, Randomized, Single-masked, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 1.0% VVN461 Ophthalmic Solution in Patients With Non-infectious Anterior Uveitis","Inclusion Criteria:\n\n* At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive);\n* At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);\n* At screening, the ACC grade of the affected eye is 2+ or 3+ \\[SUN criteria\\];\n* At screening, the ACF grade of the affected eye is ≥1 \\[SUN criteria\\];\n\nExclusion Criteria:\n\n* At screening, the affected eye has an ACC grade of 4+ or hypopyon\n* Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening","ALL","18 Years","70 Years",{"count":48,"type":49},152,"ESTIMATED","INTERVENTIONAL",[52],"PHASE3","This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China",[55],"Non-infectious Anterior Uveitis","NOT_YET_RECRUITING","2025-08-15",{"date":59,"type":60},"2025-08-22","ACTUAL",{"date":62,"type":49},"2025-10-01",{"date":64,"type":49},"2027-04-30",{"name":5,"class":6}]